Treatment outcome | ALU (N = 114) | DHP (N = 89) |
---|---|---|
ETF | 0 (0%) | 0 (0%) |
LCF, n (%) | 1 (0.88%) | 0 (0%) |
LPF, n (%) | 5 (4.39%) | 1 (1.12%) |
ACPR, n (%) | 108 (94.74%) | 88 (98.88%) |
PCR corrected | ||
ETF | 0 | 0 |
LCF, n (%) | 1 (0.88) | 0 |
LPF, n (%) | 4 (3.54) | 1 (1.12) |
ACPR, n (%) | 109 (95.58) | 88 (98.88) |
Parasite persistence | ||
Positive blood smear | ||
Day 1, n (%) | 50 (43.10) | 36 (40.45) |
Day 2, n (%) | 3 (2.59) | 1 (1.12) |
Day 3, n (%) | 0 | 0 |